Latanoprostene bunod

CAS No:

860005-21-6

Molecular Formula：

C27H41NO8

Molecular Weight：

507.62

Storage:

Store in a tightly closed container in a cool, dry，Protect from moisture and direct sunlight.

Download Product Documents

If documents are missing, please contact customer service.

Request a Quote

Technical Data

Description

Clorless or light yellow Oil

Identification

NMR HPLC

Purity

≥98

Description

PF-3187207 (latanoprostene bunod) demonstrated potent ocular hypotensive effects in preclinical models. In primates with laser-induced ocular hypertension, topical administration of 0.036% and 0.12% latanoprostene bunod reduced intraocular pressure (IOP) by up to 31% and 35%, respectively, outperforming latanoprost 0.1%, which achieved a maximum 26% IOP reduction. The dual action involves prostaglandin-mediated enhancement of uveoscleral outflow and nitric oxide-induced relaxation of the trabecular meshwork, increasing aqueous humor outflow. This combined mechanism led to sustained and significant IOP lowering without notable adverse effects. These results support its potential as an effective treatment for glaucoma and ocular hypertension by improving aqueous humor drainage through complementary pathways.

Safety Information

GHS

Pictogram:

GHS02GHS07

Signal Word:

Danger

Hazard Statements:

H225 Highly flammable liquid and vapor.
H319 Causes serious eye irritation.

Precautionary Statements:

P210 Keep away from heat/sparks/open flames/hot surfaces. – No smoking.
P233 Keep container tightly closed.
P240 Ground/bond container and receiving equipment.
P241 Use explosion-proof electrical/ventilating/lighting/equipment.
P242 Use only non-sparking tools.
P243 Take precautionary measures against static discharge.
P264 Wash thoroughly after handling.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P303+P361+P353 If on skin (or hair): Take off immediately all contaminated clothing. Rinse skin with
water/shower.
P305+P351+P338 If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if
present and easy to do. Continue rinsing.
P337+P313 If eye irritation persists: Get medical advice/attention.
P370+P378 In case of fire: Use CO2, powder or water spray to extinguish.
P403+P235 Store in a well-ventilated place. Keep cool.
P501 Dispose of contents/container in accordance with local/regional/national/international
regulations.

References

  1. El-Nimri NW, Moghimi S, Penteado RC, Ghahari E, Yang D, Brye N, Proudfoot J, Do JL, Camp A, Salcedo M, Rubio V, Weinreb RN. Comparison of the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density: A Randomized Clinical Trial. Am J Ophthalmol. 2022 Sep;241:120-129. PMID: 35526590; PMCID: PMC9444916.

  2. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Latanoprostene Bunod. 2022 Apr 18. PMID: 30000019.

  3. Bahr T, Woolf S, Favre H, Waldman C. Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma. Can J Ophthalmol. 2023 Aug;58(4):356-360. PMID: 35421360.

  4. Desai SJ, Pumphrey SA, Koethe B. Comparative effects of latanoprost and latanoprostene bunod on intraocular pressure and pupil size in ophthalmologically normal Beagle dogs. Vet Ophthalmol. 2022 Jul;25(4):282-290. PMID: 35247289.

  5. Samaha D, Diaconu V, Bouchard JF, Desalliers C, Dupont A. Effect of Latanoprostene Bunod on Optic Nerve Head Blood Flow. Optom Vis Sci. 2022 Feb 1;99(2):172-176. PMID: 34889858.

  6. Radell JE, Sharma HK, Auyeung KL, Paul ME, Gagliuso DJ, Chadha N, Tsai JC, Serle JB. Two-Year Experience With Latanoprostene Bunod in Clinical Practice. J Glaucoma. 2021 Sep 1;30(9):776-780. PMID: 34172630.

  7. Hébert M, Gravel JF, You E, Qi SR, Lajoie C. Cystoid macular edema secondary to latanoprostene bunod. Can J Ophthalmol. 2021 Dec;56(6):e185-e187. PMID: 34048726.

  8. Mehta AA, Kanu LN, Sood-Mendiratta S, Quinones R, Hawkins A, Lehrer RA, Malhotra K, Papas R, Hillman D, Wilensky JT, Aref AA, Vajaranant TS, Edward DP. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma. Eur J Ophthalmol. 2022 Jan;32(1):322-326. PMID: 33653172.

  9. Harasymowycz P, Royer C, Cui AX, Barbeau M, Jobin-Gervais K, Mathurin K, Lachaine J, Beauchemin C. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol. 2022 May;106(5):640-647. PMID: 33397657; PMCID: PMC9046749.

  10. Ostler E, Rhee D, Burney E, Sozeri Y. Advances in medical therapy for glaucoma. Curr Opin Ophthalmol. 2021 Mar 1;32(2):129-133. PMID: 33395110.

  11. Wang Y, Liao Y, Nie X. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma. Clinics (Sao Paulo). 2020 Nov 30;75:e1874. PMID: 33263632; PMCID: PMC7688071.

  12. Patel PD, Kasetti RB, Sonkusare SK, Zode GS. Technical brief: Direct, real-time electrochemical measurement of nitric oxide in ex vivo cultured human corneoscleral segments. Mol Vis. 2020 Jun 5;26:434-444. PMID: 32565671; PMCID: PMC7300198.

  13. Mehran NA, Sinha S, Razeghinejad R. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. Eye (Lond). 2020 Jan;34(1):72-88. PMID: 31695162; PMCID: PMC7002400.

  14. Fingeret M, Gaddie IB, Bloomenstein M. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension. Clin Exp Optom. 2019 Nov;102(6):541-550. PMID: 30614563; PMCID: PMC6899723.

  15. Hussar DA. New Drugs 2018, part 3. Nursing. 2018 Oct;48(10):32-43. PMID: 30192268.

  16. Two new drugs for glaucoma. Med Lett Drugs Ther. 2018 Jul 16;60(1551):117-120. PMID: 30036347.

  17. Hoy SM. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. Drugs. 2018 May;78(7):773-780. PMID: 29761382; PMCID: PMC5976683. (Erratum in: Drugs. 2018 Jun;78(8):857)

  18. Andrés-Guerrero V, García-Feijoo J. Nitric oxide-donating compounds for IOP lowering in glaucoma. Arch Soc Esp Oftalmol (Engl Ed). 2018 Jun;93(6):290-299. PMID: 29580758.

Q & A / Review

Reviews

There are no reviews yet.

Be the first to review “Latanoprostene bunod”

Your email address will not be published. Required fields are marked *